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Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in
patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation
(PRoBE) design. A total of 50 cholangiocarcinoma and 50 benign biliary tract disease cases were randomly selected from a
cohort of consecutive cases of biliary tract diseases. Their sera were measured for the levels of NGAL and the widely used serum
cholangiocarcinoma marker, carbohydrate antigen 19-9 (CA19-9). Results. The serum CA19-9 and NGAL levels were signiﬁcantly
elevated in cholangiocarcinoma patients (CA19-9: P<. 001, NGAL: P<. 001). The area under the curve (AUC) of a receiver
operating characteristic (ROC) curve analysis for the diagnosis of cholangiocarcinoma of CA19-9 and NGAL was 0.81 and 0.79,
respectively. Conclusion. The diagnostic accuracy of serum NGAL and CA19-9 makes them good candidates for use as biomarkers
to discriminate cholangiocarcinoma patients from benign biliary tract disease patients.
1.Introduction
Cholangiocarcinoma (CCA) is one of the most aggressive
malignant tumors and is associated with local invasiveness
and a high rate of metastasis [1, 2]. Most cholangiocar-
cinoma patients present with symptoms of biliary tract
obstruction. However, many cases of benign biliary tract
diseases also present with similar clinical symptoms [3].
In addition, this tumor typically grows along the bile
duct without projecting outward from the bile ducts as a
forming mass. Computed tomography (CT), ultrasound,
andmagneticresonanceimaging(MRI)areofteninadequate
to reveal this lesion [4]. Therefore, identiﬁcation of tumor
markers in the serum would be beneﬁcial in the clinical
management of this disease.
Neutrophil gelatinase-associated lipocalin (NGAL) is a
25kDaglycoproteinthatbelongstothelipocalinsuperfamily
and is characterized by its low molecular weight and its
ability to bind to and transport a variety of hydrophobic
ligands such as fatty acids, retinoids, and pheromones [5].
High NGAL expression has been reported in various cancers
including colon cancer [6], breast cancer [7, 8], ovarian
cancer [9], pancreatic cancer [10], and lung cancer [11].
Recently, we detected the expression of NGAL protein by
immunohistochemistry in 24 paraﬃn-embedded cholangio-
carcinomaspecimens.Wefoundthatallcholangiocarcinoma
specimens (24/24 cases) demonstrated the signaling for
NGAL expression and intense expression of NGAL protein
was noted in 75.0% (18/24 cases) of cholangiocarcinoma
specimens [12]. In addition, we demonstrated that knock-
down of NGAL gene expression by siRNA signiﬁcantly sup-
pressed in vitro invasiveness activity of cholangiocarcinoma
cells [12].
Previous studies showed that the serum level of NGAL
is signiﬁcantly elevated in many types of cancers, including
gastric cancer, nonsmall cell lung cancer, and hepatocellular
carcinoma [13–15]. However, there are no studies on the
serum levels of NGAL in cholangiocarcinoma patients.
Therefore, the aim of the present study was to determine
serum NGAL concentrations in these patients. In addition,
the diagnostic sensitivity, speciﬁcity and area under the
receiver operating characteristic (ROC) curves of serum2 International Journal of Hepatology
NGAL for diﬀerentiating cholangiocarcinoma from benign
biliary tract disease patients were deﬁned and compared
with the values of carbohydrate antigen 19-9 (CA19-9),
which is the common marker for cholangiocarcinoma [16,
17]. To avoid selection bias, this study was designed as
an e s t e dc a s ec o n t r o ls t u d y[ 18] that involved prospective
collection of specimens before outcome ascertainment from
a study cohort of patients with symptoms of biliary tract
obstruction. The serum values of NGAL and CA19-9 were
assayed in a blinded fashion in sera from randomly selected
case patients (cholangiocarcinoma) and control subjects
(benign biliary tract diseases) within the study cohort.
2.MaterialsandMethods
2.1. Study Design. This study was performed within the
Department of Surgery, Rajavithi Hospital. The local ethics
committee approved the study protocol. Sample size was
determined on the basis of an expected area under the
ROC curve of NGAL serum levels for the diagnosis of
cholangiocarcinoma. There are no previous studies con-
cerning the accuracy of serum NGAL in the diagnosis of
cholangiocarcinoma. Therefore, we suggested that for the
detection of serum NGAL to be clinically helpful, the area
under the ROC curve (AUC) of serum NGAL should be
higher than 0.70 in the diagnosis of cholangiocarcinoma. By
using a signiﬁcance level of 0.05 (two-sided) and a power of
0.95, we determined that a sample of 50 cholangiocarcinoma
patients was required for the study [19]. This study was
carried out according to a prospective-specimen-collection,
retrospective-blinded-evaluation (PRoBE) design [18]. We
prospectively included consecutive patients with symptoms
of obstructive jaundice who had undergone ERCP, PTBD, or
bile duct surgery during a period from June 2008 to March
2010. After the diagnosis of these patients was ascertained,
we randomly selected 50 cases of cholangiocarcinoma and
50 cases of benign biliary tract diseases and assayed their
values of serum NGAL. Because increased serum NGAL
concentrations have also been found in renal insuﬃciency
conditions [20], we therefore excluded patients with renal
insuﬃciency.
2.2. Serum Collection and the Measurement of Serum
Biochemistry. After receiving informed consent from the
patients, 5mL fasting peripheral venous blood was collected
at the time before the procedures (ERCP, PTBD, or bile duct
surgery). The serum was separated and stored at −78◦C
within 2h. Assays for the serum levels of albumin, globulin,
AST, ALT, total and direct bilirubin, alkaline phosphatase
(ALP),andCA19-9wereconductedusingroutineautomated
methods in the Rajavithi Hospital Pathological Laboratory.
2.3.MeasurementofSerumNGALLevels. Theserumlevelsof
NGAL were measured using an enzyme-linked immunosor-
bent assay (ELISA) kit (R&D Systems, Minneapolis, MN).
The diluted serum samples were added in duplicate to 96-
well plates coated with NGAL antibody. After incubation at
room temperature for two hours, the conjugated secondary
antibody was added. The substrate solution was then added
to the plates and incubated for one hour. Following termi-
nation of the reaction with the stop solution (1M sulfuric
acid), the optical density was measured at 450nm using a
spectrophotometric microplate reader. The concentration of
NGAL in each sample was calculated from a standard curve.
The scientist examining these serum specimens was blinded
to the patient’s diagnosis.
2.4. Statistical Analysis. Data are presented as the mean
± SD, unless otherwise stated. Comparisons between the
quantitative variables were performed using the Mann-
Whitney U or Student’s t-test, as appropriate. Qualitative
variables were reported as counts, and comparisons between
independent groups were performed using Pearson Chi-
squared tests. P values <.05 were considered signiﬁcant.
An ROC curve was generated by plotting the sensitivity
against 1-speciﬁcity, and the area under the curve with
95% conﬁdence intervals was calculated. The optimal cut-
oﬀ points for NGAL were selected based on the ROC curve
analysis. Sensitivity, speciﬁcity, positive predictive value, and
negative predictive values were calculated using a 2 × 2t a b l e
of the collected data.
3. Results
3.1. Patient Characteristics. A total of 221 obstructive jaun-
dice patients were enrolled. Then 50 cholangiocarcinoma
and 50 benign biliary tract disease cases were randomly
selected. The benign biliary tract diseases (control group)
included intrahepatic duct stones (6 cases), common bile
duct stones (42 cases), and benign bile duct strictures (2
cases). The cholangiocarcinoma cases included perihilar
cholangiocarcinoma (36 cases), intrahepatic cholangiocar-
cinoma (9 cases), and middle and distal common bile
duct cancer (5 cases). As shown in Table 1, no statistically
signiﬁcantdiﬀerencesingender,age,serumBUN,creatinine,
globulin, and ALT levels were identiﬁed among the data
from the control patients when compared to the cholangio-
carcinoma patients. However, the levels of serum bilirubin
and ALP were signiﬁcantly higher in cholangiocarcinoma
patients than in the control patients.
3.2. Serum Levels of CA19-9 and NGAL in Cholangio-
carcinoma and Benign Biliary Tract Diseases. The serum
CA19-9 and NGAL levels were compared between the
two disease groups. The median values of serum CA19-
9 and NGAL levels in the control group were 10.6U/mL
(range: 0.60–3660.00ng/mL) and 80.7ng/mL (range: 29.71–
261.07ng/mL), respectively. The median values of serum
CA19-9 and NGAL levels in the cholangiocarcinoma
group were 636.7U/mL (range: 0.6–71,000U/mL) and
156.15ng/mL (range: 56.49–280.77ng/mL), respectively. As
shown in Figures 1(a) and 1(b), serum CA19-9 and NGAL
values were signiﬁcantly higher in cholangiocarcinoma cases
when compared to the control patients (CA19-9: Mann-
Whitney U test; P<. 001 and NGAL: Mann-Whitney U test;
P<. 001).International Journal of Hepatology 3
Table 1: Clinical characteristics of patients with benign biliary tract diseases (control) and cholangiocarcinoma.
Control
N = 50
Cholangiocarcinoma
N = 50 Pv a l u e
Age (yr) 61 ±17 60 ±9 .898
Sex (male:female) 15:35 19:31 .527
Albumin (mg/dL) 3.9 ±0.73 3.0 ±0.55 <.001
BUN (mg/dL) 14.7 ±8.40 22.3 ±28.74 0.107
Creatinine (mg/dL) 0.9 ±0.75 1.1 ±1.16 0.358
Globulin (mg/dL) 3.8 ±0.69 4.1 ±0.94 0.098
Total bilirubin (mg/dL) 2.7 ± 4.13 13.6 ± 11.56 <.001
AST (U/L) 63.4 ±95.80 103.3 ±77.77 0.001
ALT (U/L) 62.1 ±80.13 56.8 ±44.54 0.188
ALP (U/L) 253.5±319.22 411.7 ±312.60 <.001
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Figure 1: Serum levels of NGAL and CA19-9 in cholangiocarcinoma and control (benign biliary tract disease) patients. (a) Box plots
comparing levels of NGAL and (b) CA19-9 between cholangiocarcinoma and control are illustrated. (c) Box plots comparing levels of
NGAL and (d) CA19-9 between early and advanced stages of cholangiocarcinoma and control are illustrated. Levels of NGAL are presented
as ng/mL, whereas CA19-9 is presented with the log data to accommodate the wide range. (∗; Mann-Whitney U; P<. 001 compared to
control, ∗∗;S t u d e n t ’ st-test; P<. 001 compared to control, ∗∗∗; Kruskal-Wallis test; P<. 001 compared to control, ∗∗∗∗;A N O V A ;P<. 001
compared to control).4 International Journal of Hepatology
Table 2: Pearson’s correlation coeﬃcients of NGAL, CA19-9, BUN, creatinine, albumin, total bilirubin, AST, ALT and ALP.
Pearson correlation CA19-9 BUN Creatinine Albumin Total bilirubin AST ALT ALP
NGAL 0.26∗ 0.21 0.09 −0.61
∗ 0.43
∗ 0.22 −0.055 0.02
CA19-9 0.26∗ 0.09 0.08 −0.40
∗ 0.40
∗ 0.08 −0.04 0.17
∗Statistically signiﬁcant; P<. 05.
Table 3: Performance of the biomarkers for the diagnosis of cholangiocarcinoma.
Tumor Markers
(cut-oﬀ value)
Sensitivity (%)
(95% CI)
Speciﬁcity (%)
(95% CI)
LR+ (%)
(95% CI)
LR- (%)
(95% CI)
NGAL 100 26 1.35 —
(50ng/mL) (-) (14–38) (1.35–1.59) (-)
NGAL 76 72 2.71 0.33
(110ng/mL) (64–88) (60–84) (1.69–4.35) (0.20–0.56)
CA19-9 76 74 2.96 0.32
(35U/mL) (64–88) (62–86) (1.79–4.79) (0.19–0.55)
CA19-9 72 86 5.14 0.33
(100U/mL) (60–84) (76–96) (2.53–10.44) (0.21–0.51)
Combined
markers∗
90 66 2.65 0.15
(82–98) (53–79) (1.78–3.94) (0.06–0.36)
LR+; positive likelihood ratio, LR; negative likelihood ratio, CI; conﬁdence interval. ∗; Combination of NGAL (cut-oﬀ value = 110ng/mL) and CA19-9 (cut-
oﬀ value = 100U/mL).
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Figure 2: ROC curve analyses of NGAL and CA19-9 for the
diagnosis of cholangiocarcinoma. The diagnostic accuracy of each
biomarker, in terms of its sensitivity and speciﬁcity, is presented by
receiver operating characteristic (ROC) curve analysis.
Moreover,wealsoclassiﬁedcholangiocarcinomapatients
into two groups: early (TNM stage I and II; 8 patients) and
advanced (TNM stage III and IV; 42 patients) stages. The
data shown in Figure 1(c) demonstrate that the NGAL levels
tended to increase according to the progression of cholan-
giocarcinoma. The serum NGAL values were signiﬁcantly
diﬀerentbetweenearlyandlatestagesofcholangiocarcinoma
(ANOVA; P<. 001). Although the serum CA19-9 values in
the early and late stages of cholangiocarcinoma were signif-
icantly higher than in the controls (Kruskal-Wallis test; P<
.001), the values were not signiﬁcantly diﬀerent between the
early and late stages of cholangiocarcinoma (Figure 1(d)).
3.3. Correlation between NGAL, CA19-9, and Other Blood
Chemistry. The correlation between the values of serum
BUN, creatinine, albumin, AST, ALT, ALP, total bilirubin,
CA19-9 and NGAL were investigated. As presented in
Table 2, the level of serum NGAL was signiﬁcantly correlated
with serum CA19-9, albumin, and total bilirubin, although
none of these parameters have a large Pearson’s correlation
coeﬃcient (>0.7). We suggest that the signiﬁcant correlation
ofthesebloodchemistrieswithserumNGALiscausedbythe
high number of samples used in this study.
3.4. Serum Levels of CA19-9 and NGAL for the Diagnosis
of Cholangiocarcinoma. The diagnostic accuracy of serum
CA19-9 and NGAL levels for diﬀerentiating cholangiocar-
cinoma from benign bile duct diseases was tested using an
ROC curve analysis. The AUC of the ROC curve for serum
CA19-9 and NGAL was 0.81 (95% CI 0.725–0.899) and 0.79
(95%CI0.703–0.811),respectively(Figure 2).Thesensitivity
and speciﬁcity and positive and negative predictive values for
selected cut-oﬀ points of CA19-9 and NGAL are presented in
Table 3. The sensitivity of the combination of serum CA19-9
and NGAL in these patients is considerably better than either
alone, with a combined sensitivity of 90%, and a combined
speciﬁcity of 66% (slightly reduced).International Journal of Hepatology 5
4. Discussion
To our knowledge, this is the ﬁrst study to assess serum
NGAL and CA19-9 levels in patients with cholangiocarci-
noma. Until now, there are two common tumor markers
used for detecting cholangiocarcinoma, carcinoembryonic
antigen (CEA), and CA19-9 [16]. CEA is nonspeciﬁc and
can be elevated in the setting of other gastrointestinal or
gynecologic malignancies or other bile duct pathologies,
such as cholangitis and hepatolithiasis [21]. Our previous
study demonstrated that the sensitivity and speciﬁcity of
CEA as a marker for detecting cholangiocarcinoma are only
58.54% and 62.50%, respectively [17]. Therefore, we did not
include the measurement of serum CEA in this study. Here,
we demonstrated the statistically signiﬁcant diﬀerence in the
serum NGAL levels between cholangiocarcinoma patients
and control patients (benign biliary tract diseases). When
comparingtheAUCoftheROCcurveforCA19-9andNGAL
with a chance value equal to 0.5 (the worst value of AUC
of ROC), both the AUC of the ROC for CA19-9 and NGAL
were signiﬁcantly higher than 0.5. This study demonstrated
that the sensitivity of the combination of serum CA19-9 and
NGAL for the detection of cholangiocarcinoma is promising
(a combined sensitivity of 94%). This ﬁnding indicates that
the serum values of CA19-9 and NGAL may be used as a
biomarker to discriminate cholangiocarcinoma from benign
biliary tract disease patients.
Although, in this study the signiﬁcant diﬀerences
between the cholangiocarcinoma and benign biliary tract
diseases patients regarding to the values of serum AST, ALT,
total bilirubin and albumin were identiﬁed. The Pearson’s
correlation coeﬃcient between these serum biochemistries
and serum NGAL was not high (<0.7). We suggest that
the value of NGAL does not depend on these serum
biochemistries.However,furtherstudies,whichclassiﬁedthe
value of serum NGAL in the patients with diﬀerent levels of
these serum biochemistries should be performed.
The strength of the present study was in the imple-
mentation of PRoBE designs to avoid the problems of
bias that may aﬀect studies of the diagnostic test [18].
We collected serum from all obstructive jaundice patients
before the diagnosis of cholangiocarcinoma or benign biliary
tract diseases had been determined. This procedure ensured
that biases related to diﬀerences in sample collection and
handling would be avoided. Limitations of this design
include the fact that the majority of the study participants
were in advanced stages of cholangiocarcinoma. The num-
ber of patients with early-stage cholangiocarcinoma was
small (n = 8). Further prospective multicentric studies,
which should include a greater number of early-stage
cholangiocarcinoma cases, need to be done to evaluate the
roles of NGAL in early detection of cholangiocarcinoma,
correlation with the grade of cholangiocarcinoma, and
oncologic followup should be performed. In addition, this
study was performed in the referral center, which has a
high prevalence of cholangiocarcinoma cases. As a result, the
ﬁndings may not be broadly applicable to other hospitals
that typically have a lower volume of cholangiocarcinoma
cases.
Inconclusion,thisstudydemonstratedthatserumNGAL
and CA19-9 levels are signiﬁcantly elevated in cholangiocar-
cinoma patients. These markers have the potential to be used
as tumor markers for the discrimination of cholangiocarci-
noma patients from benign biliary tract disease patients.
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